Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 706 AL 720

Initial Real-World Evidence for Lecanemab in the United States

Brixner DI, Zhao C, Toyosaki H, Frech FH, Rosenbloom MH.

Drugs Aging. 2026 Jan;43(1):69-76. doi: 10.1007/s40266-025-01261-x. Epub 2025 Oct 29.

The effects of Lithium on Beta-amyloid deposition and tau phosphorylation: A systematic review

Xiao K, Sayed H, Xing J, Zhang XY, Ai J, Kirichek E, Le GH, Wong S, Valentino K, Teopiz KM, Vinberg M, Rosenblat JD, Lo HKY, Zhang MC, McIntyre RS.

J Affect Disord. 2026 Feb 15;395(Pt A):120721. doi: 10.1016/j.jad.2025.120721. Epub 2025 Nov 17.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C.

Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7. Epub 2025 Dec 1.

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, Tronchin G, Sato S, Raket LL, Andersen SW, Sapin C, Paget MA, Gueorguieva I, Ardayfio P, Khanna R, Brooks DA, Matthews BR, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative.

J Prev Alzheimers Dis. 2026 Feb;13(2):100446. doi: 10.1016/j.tjpad.2025.100446. Epub 2025 Dec 1.

Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies

Baviskar PS, Mahajan HS.

Ageing Res Rev. 2026 Jan;114:102990. doi: 10.1016/j.arr.2025.102990. Epub 2025 Dec 10.

An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease (2021-present)

Begines P, Fernández-Bolaños JG, López Ó.

Expert Opin Ther Pat. 2026 Feb;36(2):159-190. doi: 10.1080/13543776.2025.2602702. Epub 2025 Dec 23.

Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

Silva AMP, Gonçalves OR, Tudella GCN, Nascimento MVS, Pereira MAOM, Nantes LAO, Fernandes JVA, Quiroga DG, Lima DVS Jr, Franco ES, Maia MBS.

Rev Neurol (Paris). 2026 Jan-Feb;182(1-2):36-48. doi: 10.1016/j.neurol.2025.11.005. Epub 2025 Dec 22.

Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis

Kandeel M, Mahmoud M.

J Alzheimers Dis. 2026 Feb;109(3):1089-1098. doi: 10.1177/13872877251404500. Epub 2025 Dec 8.

Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

da Silva AMP, Falcão L, Virgilio Ribeiro F, Ogasawara Donato K, Machado Magalhães PL, Nascimento MDVS, Leite M, Lee Han M, Quiroga DG, de Souza Franco E, de Sousa Maia MB.

J Geriatr Psychiatry Neurol. 2026 May;39(3):249-260. doi: 10.1177/08919887251369893. Epub 2025 Aug 22.

Efficacy and Safety of Lithium for Behavioral and Cognitive Symptoms in Alzheimer's Disease Dementia: A Systematic Review With Frequentist and Bayesian Meta-Analysis

Pereira da Silva AM, de Deus O, Ribeiro FV, Tudella GCN, Cabeça LS, Silva LL, Han ML, Franco JO, Costa JGP, Santos do Nascimento MDV, Andrade Fernandes JV, Franco ES, de Sousa Maia MB.

Am J Geriatr Psychiatry. 2026 Mar;34(3):371-385. doi: 10.1016/j.jagp.2025.10.001. Epub 2025 Oct 4.

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Sabbagh MN, Cummings JL, Ballard C, van der Flier WM, Heneka MT, Holst JJ, Knudsen LB, Salloway S, Tansey MG, Drucker DJ.

Nat Aging. 2026 Jan;6(1):56-67. doi: 10.1038/s43587-025-01029-3. Epub 2025 Dec 19.

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease

Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP.

Am J Geriatr Psychiatry. 2026 Feb;34(2):167-179. doi: 10.1016/j.jagp.2025.10.011. Epub 2025 Nov 10.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer's disease: a systematic review and meta-analysis of preclinical and clinical studies

Yoon J, Ha H, Lee HW, Kim S, Yu YM, Chun H.

Mol Psychiatry. 2026 Feb;31(2):1156-1166. doi: 10.1038/s41380-025-03413-2. Epub 2025 Dec 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias